Roche Holding AG (0QOK) Share Price & Analysis
0QOK Stock Chart & Stats
- Day’s Range
- CHF 400.80 - CHF 405.90
- 52-Week Range
- CHF 258.40 - CHF 405.90
- Previous Close
- CHF 401.95
- Volume
- 1.36M
- Average Volume (3M)
- 251.19K
- Market Cap
- CHF 321.78B
- Enterprise Value
- CHF 294.66B
- Total Cash (Recent Filing)
- CHF 9.73B
- Total Debt (Recent Filing)
- CHF 31.80B
- Price to Earnings (P/E)
- 26.3
- Beta
- 0.97
- Next Earnings
- Jan 28, 2027 (Est.)
- EPS Estimate
- 9.62
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.36%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Roche’s strong operating and free cash flow provides substantial internal funding for research, acquisitions, dividends, and debt management. High free-cash-flow conversion also supports earnings quality and gives the company resilience to absorb pipeline investment or temporary operating pressure.
Margin Expansion
Operating profit growing faster than sales indicates meaningful operating leverage and improving efficiency across the business. If sustained, the margin expansion can strengthen earnings durability, support continued investment in innovation, and provide protection against moderate pricing or competitive pressure.
Pipeline And Portfolio Momentum
Regulatory progress and strong late-stage trial execution improve Roche’s ability to replenish and broaden its product portfolio. A diversified pipeline across oncology, immunology, neuroscience, and other areas can support future growth and reduce reliance on any single established franchise.
Bears Say
Loss-of-Exclusivity Pressure
Expected loss of exclusivity creates a continuing revenue and profit headwind as mature medicines face generic or biosimilar competition. Even with pipeline launches, Roche must replace this erosion through new indications, volume growth, and successful commercialization of newer therapies.
China Diagnostics Weakness
China’s pricing reform can pressure both demand and realized pricing in Roche’s diagnostics business, making recovery dependent on policy evolution and customer adaptation. A prolonged effect would weigh on the division’s growth and could limit its ability to offset weakness in other testing markets.
Higher Net Debt
The increase in net debt reduces financial flexibility relative to Roche’s prior position, particularly while the company continues funding dividends, acquisitions, and research. Although cash generation is strong, a larger debt burden can constrain capital allocation and increase sensitivity to future cash-flow volatility.
Roche Holding AG News
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
What is Roche Holding AG’s market cap?
When is Roche Holding AG’s upcoming earnings report date?
How were Roche Holding AG’s earnings last quarter?
Is Roche Holding AG overvalued?
Does Roche Holding AG pay dividends?
What is Roche Holding AG’s EPS estimate?
How many shares outstanding does Roche Holding AG have?
What happened to Roche Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Roche Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Roche Holding AG
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Thomas Schinecker
- Employees
- 103,249
- Website
- www.roche.com
- Address
- Grenzacherstrasse 124, Basel, BS, 4070, CH
Roche Holding AG (0QOK) Earnings & Revenues
0QOK Company Deck
0QOK Earnings Call
Earnings Call SentimentPositive
The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.
View all GB:0QOK earnings summaries0QOK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |